The Swiss Market Index slipped back into the red on Wednesday, closing 0.58% lower, as investors digest a fresh batch of economic data prints and corporate updates while awaiting the US Federal Reserve's monetary policy decision.
"With a 32% chance of a rate hike today priced as of last night, this is the most uncertain that the market has been on whether the Fed will change rates going into a meeting since December 2018, when the eventual 25bps rate hike was about 65% priced the day before," analysts at Deutsche Bank Research said. "In terms of today's decision, our US economists expect the Fed to leave rates unchanged but see the risks of a hike as significant with the renewed escalation in the Middle East complicating the inflation outlook. If the Fed holds rates steady, they expect at least a couple of dissents in favour of a hike."
Speaking of the Middle East, oil prices edged higher as tensions in the region escalated after coordinated US-Saudi Arabian airstrikes killed 20 Iran-backed paramilitary members in Iraq in retaliation for drone attacks on Saudi energy facilities. Reuters said the latest development followed Tehran's rejection of an Omani proposal for joint control of the Strait of Hormuz.
Back home, data from UBS & CFA Society Switzerland showed that the country's economic sentiment index improved to 10 points in July from -25 points in June, reaching its highest level in 2026 despite the renewed geopolitical tensions. A majority of the analysts surveyed also expect the Swiss National Bank (SNBN.SW) to maintain its key rate at 0% over the next 12 months.
Over to corporates, UBS Group (UBSG.SW) posted a year-over-year increase in first-half 2026 net profit attributable to shareholders to $5.84 billion from $4.09 billion, while total revenue climbed to $27.94 billion from $24.67 billion. The Swiss banking group is also launching a new share repurchase program of $3 billion, which is set to run until the end of the second quarter of 2027, at the latest. The stock added 0.90% at closing.
"UBS reported a strong set of results, not unexpected post peer results. The top line benefited from supportive markets and operating leverage meant a large part went through to profits. The [share buyback] announcement points to a slower run rate than in consensus but the timeline leaves room to at least deliver in line with expectations," RBC Capital Markets said in a quick take note. "Even if low, the small positive NNA in the Americas is encouraging. There is no update on TBTF at this stage (as expected) but the parent bank ratio further increased."
Computer peripherals company Logitech International (LOGN.SW) and energy technology company Landis+Gyr Group (LAND.SW) also reported earnings.
Meanwhile, Sandoz Group (SDZ.SW) confirmed Brazil approved Owozy medication as a treatment for type 2 diabetes. The Swiss drugmaker will commercialize Owozy in the South American country in partnership with Adalvo, which also developed the drug, expecting the launch to take place in the second half. At the end of the trading day, Sandoz shares were up 3.72%.